291 related articles for article (PubMed ID: 15196797)
1. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.
Delfino MA; Stefano AV; Ferrario JE; Taravini IR; Murer MG; Gershanik OS
Behav Brain Res; 2004 Jul; 152(2):297-306. PubMed ID: 15196797
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
3. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
4. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
5. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
Dupre KB; Eskow KL; Negron G; Bishop C
Brain Res; 2007 Jul; 1158():135-43. PubMed ID: 17553470
[TBL] [Abstract][Full Text] [Related]
6. D1 priming enhances both D1- and D2-mediated rotational behavior and striatal Fos expression in 6-hydroxydopamine lesioned rats.
Pollack AE; Thomas LI
Pharmacol Biochem Behav; 2010 Jan; 94(3):346-51. PubMed ID: 19800912
[TBL] [Abstract][Full Text] [Related]
7. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
Neal-Beliveau BS; Joyce JN
Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
[TBL] [Abstract][Full Text] [Related]
8. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Zhang H; Ma L; Wang F; Chen J; Zhen X
Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
[TBL] [Abstract][Full Text] [Related]
9. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
[TBL] [Abstract][Full Text] [Related]
10. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
McPherson RJ; Marshall JF
Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
[TBL] [Abstract][Full Text] [Related]
11. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Damier P; Tremblay L; Féger J; Hirsch EC
Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
[TBL] [Abstract][Full Text] [Related]
13. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
14. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
[TBL] [Abstract][Full Text] [Related]
15. Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats.
Papathanou M; Rose S; McCreary A; Jenner P
Eur J Neurosci; 2011 Jun; 33(12):2247-54. PubMed ID: 21615558
[TBL] [Abstract][Full Text] [Related]
16. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences.
Ahmad M; Saleem S; Ahmad AS; Yousuf S; Ansari MA; Khan MB; Ishrat T; Chaturvedi RK; Agrawal AK; Islam F
J Neurochem; 2005 Apr; 93(1):94-104. PubMed ID: 15773909
[TBL] [Abstract][Full Text] [Related]
17. Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa.
Asin KE; Bednarz L; Nikkel A; Perner R
J Pharmacol Exp Ther; 1995 Jun; 273(3):1483-90. PubMed ID: 7791123
[TBL] [Abstract][Full Text] [Related]
18. Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Larramendy C; Taravini IR; Saborido MD; Ferrario JE; Murer MG; Gershanik OS
Behav Brain Res; 2008 Dec; 194(1):44-51. PubMed ID: 18638507
[TBL] [Abstract][Full Text] [Related]
19. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.
Lane EL; Cheetham SC; Jenner P
Eur J Neurosci; 2005 Jan; 21(1):179-86. PubMed ID: 15654855
[TBL] [Abstract][Full Text] [Related]
20. Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.
Tani Y; Ogata A; Koyama M; Inoue T
Eur J Pharmacol; 2010 Dec; 649(1-3):218-23. PubMed ID: 20858480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]